AMBALALSA (AMBALALSA) Fair Value & Analysis

Healthcare · IN · Market cap ₹2.5B

A AMBALALSA AMBALALSA · BSE

Price₹32.72

Fair Value₹21.92

Upside-33.0%

Quality56/100

Watch AMBALALSA for free — get notified when fair value or trend changes. Watch for free

Evidence: High Range ₹13.95 – ₹33.27

Fair value as of: Jul 5, 2026

From 23 valuation models · updated today

Share price −9.2% over the past month.

Price vs Fair Value (12 months)

12‑month range ₹23.82 – ₹37.26 · fair‑value band ₹13.95 – ₹33.27 · the ₹32.72 price screens above the ₹21.92 fair value. As of Jul 5, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

AMBALALSA (AMBALALSA) currently trades at ₹32.72, while our model-based Fair Value estimate is ₹21.92 — implying the stock looks roughly 33.0% overvalued today. We read business quality at 56/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: high).

Over the trailing twelve months, AMBALALSA generated revenue of ₹2.0B at a net margin of 8.8%. Revenue declined 0.7% year over year. It earns a return on equity of 11.9%. Net debt stands at ₹455M. Fundamentals as of Jul 5, 2026

Key figures & financial health

Revenue (TTM) ₹2.0B

Revenue growth (YoY) -0.7%

Net margin 8.8%

Return on equity 11.9%

Free cash flow ₹73.4M FY2026

P/E ratio 14.1

More key figures

Operating margin 11.1%

EPS (TTM) ₹2.32

EPS growth (YoY) +37.9%

Net debt ₹455M FY2026

Figures from reported company fundamentals (EODHD) · as of Jul 5, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

AMBALALSA reported revenue of ₹2.0B in FY2026 versus ₹2.0B in FY2022, a compound +0.7%/yr. Reported net income was ₹178M in FY2026, compounding −21.6%/yr from FY2022.

Revenue +0.7%/yr

FY22 ₹2.0B

FY23 ₹1.7B

FY24 ₹1.7B

FY25 ₹2.0B

FY26 ₹2.0B

Net income −21.6%/yr

FY22 ₹472M

FY23 ₹114M

FY24 ₹56.8M

FY25 ₹49.3M

FY26 ₹178M

Is AMBALALSA fairly valued? → Check now

Similar stocks

6 more Pharmaceuticals stocks, each showing price versus our Fair Value estimate (as of Jul 5, 2026).

Stock	Price	Fair Value	vs Fair Value
ST Pharm Co 237690	115,900 KRW	61,182 KRW	-47%
NatureCell Co 007390	33,950 KRW	901.89 KRW	-97%
Oscotec Inc 039200	38,950 KRW	34,117 KRW	-12%
DongKook Pharmaceutical Co 086450	17,280 KRW	25,989 KRW	+50%
Kolon Life Science Inc 102940	49,200 KRW	48,134 KRW	-2%
Komipharm International Co 041960	8,370 KRW	543.06 KRW	-94%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is AMBALALSA (AMBALALSA) undervalued?

As of Jul 5, 2026, our model estimates a fair value of ₹21.92 versus a price of ₹32.72 — about −33% (overvalued). Model-based estimate, not financial advice.

What is the fair value of AMBALALSA?

Our model-based fair value for AMBALALSA is ₹21.92 (as of Jul 5, 2026), built from audited fundamentals. The current price is ₹32.72.

What is the quality score of AMBALALSA?

AMBALALSA has a Quality Score of 56/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of AMBALALSA (AMBALALSA)?

AMBALALSA reported trailing-twelve-month revenue of about ₹2.0B (latest available figure, as of Jul 5, 2026).

What is the net profit margin of AMBALALSA?

The net profit margin of AMBALALSA is about 8.8%, meaning it keeps roughly 8.8% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.